News

IIT Madras Has Built a Drug Delivery Hydrogel From Silk and Seaweed That Could Replace Weeks of Daily Medication for Fibrosis Patients — at One-Tenth the Cost

By Mustafa Shariff, Editor in Chief · June 01,2026 · 2 min read

Summary

• IIT Madras's Silk-Seaweed Hydrogel: A Single Injection That Could Replace Weeks of Fibrosis Medication
• IIT Madras researchers have developed a patented injectable hydrogel from silk cocoons and seaweed for targeted fibrosis treatment. Here is the full story of the science and its significance.

"Fibroproliferative diseases, including pulmonary, liver, kidney and muscle fibrosis, are linked to nearly 45% of deaths globally. Existing treatments often require prolonged drug administration, can cause significant side effects, and are frequently unable to stop disease progression effectively at the targeted site."

Researchers at the Indian Institute of Technology Madras have developed a patented injectable hydrogel made from silk fibroin — extracted from silkworm cocoons — and seaweed-derived biomaterials that has demonstrated significant promise for the targeted, sustained treatment of fibrosis and other chronic degenerative conditions. The innovation, developed at the Tissue Engineering and Biomaterials Laboratory in the Department of Biotechnology and published in ACS Applied Bio Materials and Materials Today Bio, is designed to address a specific and profound limitation of current fibrosis treatment: the requirement for prolonged, repeated drug administration with systemic side effects and inadequate delivery to the site of disease.

Fibrosis — the pathological accumulation of excess connective tissue in organs — is not a single disease but a common pathological mechanism underlying conditions including pulmonary fibrosis, liver cirrhosis, kidney fibrosis, cardiac fibrosis, and muscle fibrosis. Professor Vignesh Muthuvijayan, who led the research, noted that fibroproliferative diseases are linked to nearly 45% of deaths globally — a statistic that underlines the scale of the unmet medical need. Current treatments require prolonged drug administration, cause significant systemic side effects, and are frequently unable to arrest disease progression at the specific tissue site where fibrosis is occurring.

What the Hydrogel Does

The IIT Madras hydrogel combines two indigenously sourced natural biomaterials. Silk fibroin — the structural protein extracted from silk cocoon fibres — provides the hydrogel's scaffold with properties including biocompatibility, biodegradability, and tunable mechanical strength. Seaweed-derived polysaccharides (alginate and related compounds) contribute hydrogel-forming properties, controlled swelling behaviour, and additional biocompatibility. Together, these materials create a three-dimensional scaffold that can be loaded with antifibrotic and anti-inflammatory drug compounds and injected directly at the target tissue site.

Once injected, the hydrogel localises at the disease site and releases its drug payload in a sustained, controlled manner over a period of weeks — replacing the daily oral or injectable dosing regimen that current fibrosis treatments require. The local delivery concentrates therapeutic drug concentrations at the disease site while reducing systemic drug exposure, addressing the side effect profile that limits the doses clinicians can safely prescribe using conventional administration routes.

Follow-up studies conducted in collaboration with the University of California San Diego demonstrated efficacy across multiple disease models — specifically including aged muscle tissue, which is particularly relevant given that fibrosis-related muscle conditions disproportionately affect older patient populations. The collaboration with UC San Diego brings international validation to a research programme that is explicitly rooted in India's indigenous material capabilities: sericulture (silk production) and marine bioeconomy (seaweed harvesting) are both sectors in which India has significant and growing infrastructure.

The Cost Reduction Potential

The economic dimension of the IIT Madras hydrogel is as significant as the clinical one. Researchers estimate that the innovation could potentially reduce treatment costs from approximately $2,000-3,000 per course of conventional fibrosis therapy to approximately $300 — a reduction of roughly 85-90%. This cost reduction stems from two factors: the elimination of weeks of repeated dosing (reducing total drug quantity required) and the use of naturally derived, indigenously sourced biomaterials that do not carry the cost burden of synthetic polymer systems or imported biological materials.

At $300 per treatment course, fibrosis therapy moves from a category accessible primarily to well-insured patients in high-income countries to one that could be within reach of patients in India and lower-middle-income countries. For pulmonary fibrosis, liver cirrhosis, and kidney fibrosis — conditions that affect significant populations in India — this cost shift has direct implications for healthcare access.

Technology Readiness and the Path Forward

IIT Madras has classified the innovation at Technology Readiness Level 4 — validated in laboratory conditions but not yet in human clinical trials. The next phases will involve advanced preclinical studies in larger animal models, optimisation of drug-release kinetics for specific fibrosis conditions, long-term safety evaluations, and manufacturing scale-up studies. IIT Madras is exploring commercialisation pathways including technology transfer, industry licensing, and potential startup creation.

BHC Perspective

At Bengaluru Health Community, the IIT Madras silk-seaweed hydrogel is the kind of research story that defines what Indian biomedical innovation should aspire to: world-class science, indigenous materials, clinical relevance for Indian patients, and potential commercial value through technology transfer. For BHC founders in drug delivery technology, biomaterials, or pharmaceutical manufacturing — this is the early-stage research that creates tomorrow's startup and licensing opportunities.

Frequently Asked Questions

Q: What has IIT Madras developed?
A: A patented injectable hydrogel made from silk fibroin (silkworm cocoons) and seaweed-based biomaterials that delivers antifibrotic and anti-inflammatory drugs directly to diseased tissue in a sustained manner — replacing weeks of repeated dosing with a single injection.

Q: How much could this reduce treatment costs?
A: From approximately $2,000-3,000 per conventional fibrosis treatment course to approximately $300 — an 85-90% cost reduction — through elimination of repeated dosing and use of indigenously sourced natural biomaterials.

Q: What is the current development stage?
A: Technology Readiness Level 4 — validated in laboratory conditions and multiple disease models (including aged muscle tissue in collaboration with UC San Diego). Advanced preclinical studies, clinical trials, and manufacturing scale-up are the next phases.